Evidence map›Paper›PMID 39144409›Full record

ArticleIET nanobiotechnology2024

Anti-Proliferative Activity of Poloxamer Cobalt Ferrite Nanoparticles against Human Prostate Cancer (DU-145) Cells: In-Vitro Study.

Nazanin Oroskhani, Seyed Mohammad Amini, Sakine Shirvalilou, Mehdi Khodaie, Seyed Rabi Mahdavi

Abstract read
In one paragraph

Article in IET nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nazanin OroskhaniDepartment of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad AminiRadiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-6447-9872
Sakine ShirvalilouFinetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-3213-8824
Mehdi KhodaieMaterials Science and Engineering, K. N. Toosi University of Technology, Tehran, Iran.ORCID https://orcid.org/0000-0003-0076-8872
Seyed Rabi MahdaviDepartment of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1973-2140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the second most frequent type of cancer death in men. This study refers to the novel hyperthermia application of poloxamer-coated cobalt ferrite as a new approach for thermal eradication of DU-145 human prostate cancerous cells under a radio frequency magnetic field (RF-MF). The hydrothermal method was applied for the synthesis of cobalt ferrite nanoparticles. Then, the structure, size, and morphology of nanoparticle were characterized. The cytotoxicity of the synthesized nanoparticles and RF-MF exposure on DU-145 prostate cancer cells was investigated separately or in combination with colony formation methods and MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay. Transmission electron microscopy (TEM) confirmed the spherical morphology of nanoparticles with a size of 5.5 ± 2.6 nm. The temperature of cells treated with nanoparticles under RF-MF reached 42.73 ± 0.2°C after 15 min. RF-MF treatment or nanoparticles have not affected cell viability significantly. However, the combination of them eradicated 53% ± 4% of cancerous cells. In-vitro hyperthermia was performed on human prostate cancer cells (DU-145) with cobalt ferrite nanoparticles at specific concentrations that demonstrated a decrease in survival fraction based on colony formation assay compared to cells that were treated alone with nanoparticles or with RF-MF.

Indexed as

Cell ProliferationCell SurvivalCobaltFerric CompoundsPoloxamerProstatic NeoplasmsAntineoplastic AgentsCell Line, TumorHumansHyperthermia, InducedMaleMetal NanoparticlesAntineoplastic AgentsCobaltcobalt ferriteFerric CompoundsPoloxamer

Identifiers

PMID39144409
PMCPMC11324361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.